To showcase the power of our technology we are currently developing conjugate VLX101 for application in treating a wide range of autoimmune diseases.

Additionally we have recently added a similar conjugate targeting proliferative disease.

We are actively looking for strong partners for co-development of our assets. If you are interested, please do not hesitate to get in touch.